CpG-DNA refers to the phosphothioate backbone containing oligonucleotide 1668 (TCCATGACGTTCCTGATGCT; TIB Molbiol). Other agonists used were LPS (E. coli 0127:B8; Sigma-Aldrich), coumermycin A1 (Sigma-Aldrich), R848 (GLSynthesis), tripalmitoyl cysteinyl lipopeptide (Pam3Cys; EMC Microcollections), and Curdlan (InvivoGen). The following antibodies were used: FLAG [M2 (soluble and bead immobilized)], β-ACTIN (Sigma-Aldrich), MyD88, IκBα, P-p38, P-JNK, P-ERK, p38, and Myc-Tag (Cell Signaling Technology), and HA (Roche); secondary antibodies were conjugated to horseradish peroxidase (GE Healthcare Life Sciences). Chemiluminescent substrate was from Thermo Fisher Scientific. ELISA kits were from eBiosciences (TNFα). Luciferase assay system was from Promega. Alamar blue assay system and Lipofectamine 2000 were from Invitrogen. Full-length human ERα and ERβ were obtained from PanVera/Invitrogen; tritiated estradiol was obtained from PerkinElmer.

Expression plasmids were established by conventional molecular biology techniques and verified by DNA sequencing. Epitope tags used consisted in tandem triple tags (HA and FLAG) or single tag (Myc), which were fused N-terminal to the complementary DNA of full-length mouse MyD88, the MyD88 DD (amino acids 2 to 109), or the MyD88 TIR domain (amino acids 157 to 296). FLAG-tagged TIRAP-GyrB was expressed as fusion protein consisting in triple FLAG-tagged, full-length mouse TIRAP, and a C-terminal GyrB moiety using a lentiviral vector containing a PGK1 promoter. FLAG-tagged MyD88-GyrB was expressed as fusion protein consisting in triple FLAG-tagged, full-length MyD88, and a C-terminal GyrB moiety using a murine stem cell virus (MSCV)–based retroviral vector (MSCV-puro; Clontech). FLAG-tagged TRAF6-GyrB was expressed as fusion protein consisting in a triple FLAG-tagged, N-terminal part of human TRAF6 (amino acids 2 to 351), and a C-terminal GyrB moiety using a pcDNA3-based vector with EF1α (elongation factor 1α) promoter.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。